Two Phase III trials of PARP inhibitors in mCRPC

There are now two, ongoing, Phase III trials of PARP inhibitors in the treatment of eligible patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Second PARP inhibitor approved by FDA (but still not for prostate cancer)

A second PARP inhibitor has recently been approved by the US Food and Drug Administration (FDA) for the treatment of patients with BRCA1/2 mutations and advanced ovarian cancer who have already received two types of chemotherapy. … READ MORE …

Maybe PD-1 inhibitors have a role in advanced prostate cancer after all!

New immunotherapeutic drugs known as PD-1 inhibitors (drugs like nivolumab/Optivo and pembrolizumab/Keytruda) have shown some remarkable effects in the treatment of advanced forms of cancer like melanoma and some forms of lung cancer. … READ MORE …

Abiraterone + veliparib in treatment of men with mCRPC

Another important set of data that came out of the ASCO session that your sitemaster was unable to attend were the data presented by Dr. Maha Hussain on the use of the PARP inhibitor veliparib.

J&J investing further in potential drugs for advanced prostate cancer

Johnson & Johnson has just acquired the rights to develop and sell a drug called niraparib for the treatment of prostate cancer everywhere in the world except Japan. The developer, Waltham, MA-based Tesaro, has retained the rights to niraparib in Japan. … READ MORE …

Published data on activity of olaparib in some men with mCRPC

A paper in the New England Journal of Medicine now provides detailed information about the activity of the PARP inhibitor olaparib in the treatment of carefully selected patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

“Lynchpin molecule for the spread of cancer found”

This type of heading in media stories and press releases tends to drive your Sitemaster to distraction because there is almost invariably a major “may” or a “possibly” in the actual story when you get into the details. However, in this particular case there may be some justification for the headline. … READ MORE …